## REGN: Regeneron Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.15 indicates fundamental undervaluation. Quality metrics strong (ROE 15%). Consistent execution (3/4 quarters beat estimates). Caution: momentum weakening (-7.6% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($659.80)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Regeneron Reports Promising Results from LINKER-MM4 Trial of Lynozyfic™ for Newly Diagnosed Multiple Myeloma**
- Source: Quiver Quantitative | 20251207T220841 | Somewhat-Bullish | Relevance: 100%
-  Regeneron Pharmaceuticals announced promising interim results from its Phase 1/2 LINKER-MM4 trial for Lynozyfic™ (linvoseltamab) in adults with newly diagnosed multiple myeloma. The trial showed that all dose groups achieved a very good partial response or better (VGPR+) of ≥70%, with a high rate of minimal residual disease negative status. Regeneron will host a virtual investor event on December 10, 2025, to discuss its multiple myeloma development program further, highlighting the drug's potential as a foundational component for frontline treatment.

**2. Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Amundi**
- Source: MarketBeat | 20251206T081310 | Somewhat-Bullish | Relevance: 99%
-  Amundi significantly reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 44.1% in Q2 2025, selling 706,770 shares, though it still holds 897,131 shares valued at $491.4 million. Despite insider selling, other institutional investors like Marshall Wace and Dodge & Cox increased their positions, with institutional ownership nearing 83.31%. Regeneron reported strong Q3 earnings, beating analyst estimates for both EPS and revenue, and maintains a "Moderate Buy" consensus with an average target price of $777.36.

**3. ASH takeaways: Regeneron unveils new data on blood cancer drugs, touts hematology pipeline**
- Source: Medical Marketing and Media | 20251209T161534 | Bullish | Relevance: 99%
-  Regeneron presented new early data on two of its blood cancer drugs, linvoseltamab and odronextamab, at the American Society of Hematology (ASH) annual conference. Linvoseltamab showed efficacy as a monotherapy in newly diagnosed multiple myeloma, with a 70% very good or partial response rate. Odronextamab, in a trial combining it with CHOP chemotherapy for diffuse large B-cell lymphoma, achieved a 100% complete response rate among 13 patients.

**4. Ossiam Sells 22,234 Shares of Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251209T122957 | Neutral | Relevance: 98%
- Ossiam reduced its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 59.5% in Q2 2025, selling 22,234 shares and retaining 15,160 shares valued at $7.959 million. Other institutional investors also adjusted their holdings, while company insiders like VP Jason Pitofsky and Director Christine A. Poon sold significant shares. Regeneron Pharmaceuticals reported strong Q3 earnings, beating analyst estimates, and announced a quarterly dividend of $0.88 per share.

**5. Federated Hermes Inc. Acquires 204,045 Shares of Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251207T120923 | Bullish | Relevance: 98%
-  Federated Hermes Inc. significantly increased its stake in Regeneron Pharmaceuticals ($REGN) by 491.2% in Q2, acquiring an additional 204,045 shares and bringing its total holdings to 245,587 shares valued at $128.93 million. This comes as other major institutions have also built substantial positions, leading to institutional investors owning 83.31% of the company. Regeneron recently surpassed EPS estimates and announced a quarterly dividend, while analysts maintain a "Moderate Buy" rating with a consensus target price of $777.36.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Canaccord Genui | $1057 | $850 | +24% |
| 2025-12-04 | BMO Capital | $850 | $725 | +17% |
| 2025-12-03 | Morgan Stanley | $767 | $767 | 0% |
| 2025-11-24 | Scotiabank | $770 | $650 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Canaccord Genui | main | Buy |
| 2025-12-04 | BMO Capital | main | Outperform |
| 2025-12-03 | Morgan Stanley | down | Equal-Weight |
| 2025-11-24 | Scotiabank | main | Sector Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($20.86M) |
| Sells | 5 ($11.41M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (-4.0%)
- Blackrock Inc.: 8.6% (-4.7%)
- JPMORGAN CHASE & CO: 7.9% (+106.7%)
- State Street Corpora: 4.5% (-2.9%)
- Dodge & Cox Inc.: 4.4% (+18.9%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-7.6% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $11M sold (5 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 4 raises (avg +18%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.15 suggests fair value with growth premium. Quality metrics strong (margin 32%). Balance sheet: strong liquidity (4.1x), low leverage (D/E 0.30), $1.4B free cash flow. Analyst sentiment positive (4 raises, avg +18%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $74.5B |
| Beta | 0.37 |
| 52W Range | $476.49 - $800.99 |
| Short Interest | 2.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.15 |
| Forward P/E | 17.8 |
| Current P/E | 16.3 |
| YoY Growth | -8.5% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 2.6% to -5.0% (-7.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 9.0pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.17x) but short-term weakness (below SMA20). MACD histogram bearish (-9.16), momentum weakening. RSI neutral at 50.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.97% (CS: 15) | Weak |
| RSI_14 | 49.9 | Neutral |
| MACD Histogram | -9.16 | Bearish |
| vs SMA20 | 0.970x | Below |
| vs SMA50 | 1.083x | Above |
| vs SMA200 | 1.174x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $703.26
- **Stop Loss:** $659.80 (6.2% risk)
- **Target:** $790.18 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 11
- **Position Value:** $7,735.86
- **Portfolio %:** 7.74%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-03 (Est: $10.77)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.64 | $11.83 | +22.7% |
| 2025Q2 | $8.44 | $12.89 | +52.7% |
| 2025Q1 | $8.48 | $8.22 | -3.0% |
| 2024Q4 | $11.19 | $12.07 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*